Latest news with #endovascular
Globe and Mail
7 hours ago
- Business
- Globe and Mail
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025. The Company remains actively engaged with the U.S. Food and Drug Administration (FDA), with a 510(k) decision now expected during the third quarter of this year. This updated FDA decision timeline remains within the FDA's original scheduled review window and is not expected to affect the Company's planned launch upon clearance. 'Our recent interactions with the FDA have been productive, and we remain confident in the process and outcome,' said Harel Gadot, Chairman, CEO & President. 'We continue to operate with full momentum and position the Company for an anticipated launch during the third quarter of this year, which includes the continued build out of our commercial infrastructure and preparing the organization to deliver on our strategy.' As part of the Company's ongoing launch preparation, it recently expanded its commercial team with the addition of Michael Lytle as the head of Sales Operations & Analytics. Mr. Lytle brings deep experience in sales support, data analysis, and operational excellence. He is expected to play a key role in shaping market intelligence tools and processes to optimize the sales cycle and drive strategic growth. Prior to joining Microbot, Mr. Lytle held increasing leadership roles at ZOLL Cardiac Management Solutions (CMS), a division of ZOLL Medical Corporation, where he supported the rollout of innovative cardiac care technologies. 'We believe that Michael's addition will strengthen our launch readiness plans, and that his expertise will help us target the right markets, allocate resources effectively, and accelerate commercial execution,' concluded Mr. Gadot. The LIBERTY System is currently under FDA review, is not available for sales in the US, and clearance is not guaranteed. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical® is available at Safe Harbor Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as 'will,' 'believes,' 'plans,' 'anticipates,' 'expects' and 'estimates') should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading 'Risk Factors' in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law
Associated Press
11-05-2025
- Health
- Associated Press
Dubai Vein Specialist: Varicose Vein Treatment in Dubai and Spider Vein Treatment in Dubai by Leading Vascular Surgeon
Dr. Soroush Sohrabi, UK-trained vascular surgeon, offers advanced varicose vein treatment in Dubai and spider vein treatment in Dubai using modern techniques. 'Today's varicose vein treatment in Dubai and spider vein treatment in Dubai offer safe, effective results with minimal downtime — helping patients return to life quickly and confidently.'— Dr. Soroush Sohrabi, Consultant Vascular & Endovascular Surgeon DUBAI, دبي — DUBAI, UNITED ARAB EMIRATES, May 11, 2025 / / -- Individuals in the UAE struggling with leg pain, visible veins, or chronic venous conditions now have access to expert care through Dr. Soroush Sohrabi, a UK-trained consultant vascular and endovascular surgeon. Renowned for his precision and patient-focused approach, Dr. Soroush Sohrabi offers state-of-the-art varicose vein treatment in Dubai and spider vein treatment in Dubai, utilizing advanced, image-guided techniques for safety, comfort, and effectiveness. Varicose veins and spider veins are common vascular issues, particularly in hot climates like Dubai, where standing for long hours or exposure to heat can aggravate symptoms. These conditions may begin as mild discomfort or purely cosmetic concerns. However, in some patients, they can progress to ongoing leg pain, swelling, pigmentation, or even skin ulceration if not addressed. Even at early stages, visible veins can impact confidence, self-image, and daily comfort. Dr. Soroush Sohrabi brings a global standard of care to the UAE with international training in the United Kingdom, Australia, and the United States. His treatment approach combines evidence-based medicine, cutting-edge technology, and individualized planning. 'Minimally invasive procedures have revolutionized varicose vein treatment in Dubai,' says Dr. Sohrabi. 'Patients can now achieve long-term relief with minimal downtime and excellent cosmetic outcomes.' Advanced Treatment Options Dr. Soroush Sohrabi specializes in non-surgical and catheter-based therapies, avoiding general anesthesia and ensuring faster recovery. His key treatment offerings include: • Endovenous Laser Ablation (EVLA): Laser energy seals the vein from within, performed under local anesthesia. • Radiofrequency Ablation (RFA): Uses heat via radiofrequency waves to collapse faulty veins with minimal discomfort. • ClariVein® Mechanochemical Ablation: Combines mechanical rotation and sclerosing agent to close veins without heat. • Ultrasound-Guided Foam Sclerotherapy: Effective for spider veins and residual varicosities using foamed sclerosants. Most procedures are outpatient, allowing patients to resume normal activity within 1–2 days. Precision Diagnostics and Personalized Planning Every treatment begins with a comprehensive Doppler ultrasound to map vein flow and detect reflux. This diagnostic step is critical for tailoring treatment to each patient's anatomy and severity. 'No two cases are the same,' Dr. Sohrabi explains. 'Personalized planning ensures that each patient receives the most effective outcome.' He also prioritizes: • Transparent education and pre-treatment discussion • Compression therapy when clinically appropriate • Structured long-term follow-up Who Can Benefit from Treatment? Patients may benefit from evaluation if they experience: • Persistent heaviness or aching in the legs • Night-time cramps • Visible spider veins or bulging varicose veins • Ankle swelling or discoloration • Skin changes or itching near the lower legs Why Choose Dr. Soroush Sohrabi? With a reputation for ethical practice, meticulous technique, and global expertise, Dr. Soroush Sohrabi is regarded among the best doctors for varicose vein treatment in Dubai and spider vein treatment in Dubai. He is among the few vascular surgeons in the UAE offering both thermal and non-thermal options, including ClariVein®, a modern, needle-sparing treatment that minimizes bruising and speeds recovery. 'I aim to restore comfort, function, and confidence with minimal disruption to life,' says Dr. Sohrabi. Booking a Consultation Consultations include: • Full Doppler ultrasound mapping • Diagnosis of venous insufficiency or other pathology • Clear explanation of conservative and interventional treatments Dr. Soroush Sohrabi treats both local UAE and international patients, offering multilingual support and timely scheduling. Learn More or Book an Appointment varicose vein treatment in Dubai spider vein treatment in Dubai About Dubai Vein Specialist Dubai Vein Specialist is the platform of Dr. Soroush Sohrabi, a UK-trained board-certified consultant offering spider vein treatment in Dubai, varicose vein treatment in Dubai, and chronic venous care. His practice emphasizes accuracy, ethics, and long-term outcomes. Disclaimer: All treatments are subject to clinical assessment. Outcomes may vary depending on condition severity, health status, and adherence to follow-up protocols. Dr. Soroush Sohrabi Dubaiveinspecialist email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
